Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The application of adeno-associated virus (AAV) vectors in large animal research and clinical trials usually require high-titer and efficient vectors. However, many currently used vector production methods based on transient transfection of cell lines or helper virus infection have their mimics.
Creative Biolabs provides innovative products and services designed to accelerate your treatment projects through the development of AAV vectors. With solutions covering the entire AAV production process, we have developed a 293 cell-based producer cell line method for high-titer and highly-potency AAV vectors.
Creative Biolabs' AAStable™ technology takes the production of viral vectors to a new level.
Through a unique producer cell line method, AAStable™ can achieve high-performance AAV vector production, thereby providing consistent quality in various types and forms of suspension bioreactors, up to large-scale production. No helper virus, expensive transfection reagent, or cGMP grade plasmid is required. Just propagate your producer cell and start production.
Our AAStable™ Platform has the following main advantages:
(1) One-step cloning of AAV vector cassettes into serotype-specific packaging plasmids;
(2) Single plasmid transfection and selection of stable AAV vector production cell lines;
(3) Use Carriers suitable for different serotypes such as AAV2, 8, and 9;
(4) Effective packaging of single-stranded and double-stranded (self-complementary) AAV vectors;
(5) Effective packaging of large AAV cassettes (~5.0 kb).
(6) All cell lines are stable and the growth rate is the same as that of the parental 293 cells.
(7) The vector shows high efficiency of transduction in vitro and in vivo.
In short, our simple and universal AAV production cell line method can be used for large-scale AAV vector production for preclinical and clinical studies.
Our goal is to provide superior product depth and expertise to help companies develop breakthrough therapies. If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
